Market Research Logo

Critical Limb Ischemia - Pipeline Review, H1 2015

Critical Limb Ischemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H1 2015’, provides an overview of the Critical Limb Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Critical Limb Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia Overview
Therapeutics Development
Pipeline Products for Critical Limb Ischemia - Overview
Pipeline Products for Critical Limb Ischemia - Comparative Analysis
Critical Limb Ischemia - Therapeutics under Development by Companies
Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes
Critical Limb Ischemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Critical Limb Ischemia - Products under Development by Companies
Critical Limb Ischemia - Products under Investigation by Universities/Institutes
Critical Limb Ischemia - Companies Involved in Therapeutics Development
AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Bioheart, Inc.
DNAVEC Corporation
Hemostemix Ltd
IntelliCell BioSciences Inc.
Juventas Therapeutics, Inc.
Kasiak Research Pvt. Ltd.
Multi Gene Vascular Systems Ltd
NeoStem, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
ReNeuron Group plc
Stempeutics Research Private Limited
TikoMed AB
Vericel Corporation
ViroMed Co., Ltd.
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alecmestencel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASCT-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Vascular Cells Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellgram for Severe Lower Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DVC1-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixmyelocel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiGeneAngio - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refacell-CLI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ReN-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stempeucel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Critical Limb Ischemia - Recent Pipeline Updates
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
May 19, 2015: Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia
May 18, 2015: Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project
May 13, 2015: Pluristem’s PLX Cells One Step Closer to Entering Japan’s Accelerated Pathway for Regenerative Medicine
Apr 27, 2015: Stempeutics Gets Stem Cell Patent in China (Chinese Application Number: CN201080053627) for its Novel Stem Cell Drug Stempeucel
Apr 20, 2015: Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
Apr 20, 2015: Pluristem’s Clinical Advisory Board Prepares Phase II Clinical Trials in Critical Limb Ischemia in Europe and Japan
Mar 19, 2015: Hemostemix Expands Clinical Trial for Critical Limb Ischemia (CLI) to Four Sites in South Africa, Treats First South African Participant
Mar 06, 2015: Hemostemix Expands Clinical Trial for Treating Critical Limb Ischemia to the Peter Munk Cardiac Centre at Toronto General Hospital
Mar 04, 2015: Stempeutics receives US process patent for its novel stem cell drug Stempeucel
Feb 19, 2015: Cynata Achieves Major Stem Cell Manufacturing Milestone
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Critical Limb Ischemia, H1 2015
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H1 2015
Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H1 2015
Critical Limb Ischemia - Pipeline by Athersys, Inc., H1 2015
Critical Limb Ischemia - Pipeline by Bioheart, Inc., H1 2015
Critical Limb Ischemia - Pipeline by DNAVEC Corporation, H1 2015
Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H1 2015
Critical Limb Ischemia - Pipeline by IntelliCell BioSciences Inc., H1 2015
Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H1 2015
Critical Limb Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H1 2015
Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015
Critical Limb Ischemia - Pipeline by NeoStem, Inc., H1 2015
Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H1 2015
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H1 2015
Critical Limb Ischemia - Pipeline by ReNeuron Group plc, H1 2015
Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H1 2015
Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2015
Critical Limb Ischemia - Pipeline by Vericel Corporation, H1 2015
Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H1 2015
Critical Limb Ischemia - Dormant Projects, H1 2015
Critical Limb Ischemia - Dormant Projects (Contd..1), H1 2015
Critical Limb Ischemia - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Critical Limb Ischemia, H1 2015
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report